LONDON, UK: The controls imposed on the export of Covid vaccine by Indian government, has suspended supply of vaccines to Bangladesh, Beximco Pharmaceuticals Limited, the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, said.
Beximco Pharma has had an agreement with the Government of Bangladesh (GOB) and the Serum Institute of India Private Limited (SII) that required SII to deliver a total of 30 million doses to GOB.
These deliveries were originally planned to be completed by 7 July 2021 (within six months of the vaccine’s regulatory approval), with Beximco Pharma to receive a separate fee for its role in storage and nationwide distribution of the vaccine. Further to the Company’s announcement on 28 April 2021, the Indian Government’s controls on vaccine exports remain in place.
SII has therefore been unable to supply any further vaccine doses to Bangladesh beyond the seven million doses that had already supplied to GOB during January and February 2021.
Beximco Pharma’s original agreement with SII and GOB remains valid until 14 June 2022 and all parties anticipate that SII will be able to re-commence exports to Bangladesh once the temporary export controls from India have been relaxed when, as previously announced, the Company will collaborate with SII to provide a revised supply schedule for GOB.